18:16 , Aug 31, 2018 |  BC Week In Review  |  Company News

SEC charges ex-Sangamo exec with insider trading

The SEC charged Winson Tang, former VP of clinical research at Sangamo Therapeutics Inc. (NASDAQ:SGMO), and others with insider trading ahead of the biotech's 2014 licensing deal with Biogen Inc. (NASDAQ:BIIB). In a filing ,...
00:44 , Apr 15, 2017 |  BioCentury  |  Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
02:11 , Dec 9, 2015 |  BC Extra  |  Company News

FDA approves Bendeka for CLL, NHL

FDA approved Bendeka bendamustine RTD ( EP-3102 ) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma that has progressed during or...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Syntonix, Biovitrum deal

Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an opt-in right from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) to take over development and commercialization of Alprolix in Europe, North Africa, Russia and 13 Middle Eastern countries....
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Isis Pharmaceuticals, Biogen Idec deal

Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the companies are using Isis’ antisense technology to identify and validate targets. The milestone was triggered by validation of an...
01:54 , Mar 24, 2015 |  BC Extra  |  Company News

Biogen drops Idec from name

Biogen (NASDAQ:BIIB) changed its name from Biogen Idec Inc. The company had been called Biogen Idec since Biogen Inc. merged with Idec Pharmaceuticals Corp. in 2003. Biogen's shares fell $12.25 to $463.73 on Monday....
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Aducanumab: Interim Phase Ib data

Interim data from 166 patients with prodromal or mild AD in the double-blind, dose-escalation, U.S. Phase Ib PRIME trial showed that 3, 6 and 10 mg/kg IV aducanumab significantly reduced mean levels of amyloid plaque,...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Gazyva obinutuzumab regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line therapy for chronic lymphocytic leukemia (CLL) in patients who have comorbidities making them unsuitable for...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Biogen Idec, Eli Lilly, GlaxoSmithKline, J&J, Pfizer, Alzheimer’s Research UK, U.K. Department of Health neurology news

The U.K. government unveiled its $100 million Dementia Discovery Fund to support dementia research. GlaxoSmithKline invested $25 million, while Johnson & Johnson invested $10 million through its venture arm, Johnson & Johnson Innovation-JJDC Inc. Other...
07:00 , Mar 23, 2015 |  BioCentury  |  Strategy

Show me the value

At a time when industry is struggling mightily with how to demonstrate the value of its products to payers and patients and translate that value into pricing, The Medicines Co. could provide some lessons. The...